Hydroquinone + Tretinoin + Mometasone

This preparation is a modified triple-combination cream, a variation on Kligman's original three-drug formula for melasma. It combines hydroquinone, a phenolic depigmenting agent that suppresses melanin production; tretinoin, the acid form of vitamin A that speeds skin-cell turnover and helps clear pigment; and mometasone (mometasone furoate), a corticosteroid included to reduce the irritation the other two ingredients cause. Whereas the reference triple cream uses the mild steroid fluocinolone acetonide, this version substitutes mometasone, a more potent corticosteroid, and the modification has become popular in some markets, particularly across South Asia ^[1].

Triple-combination therapy is the best-supported topical approach to melasma. A Cochrane systematic review found that the hydroquinone-tretinoin-corticosteroid combination lightened melasma significantly more effectively than hydroquinone alone or two-drug pairings ^[2], and evidence-based reviews place triple-combination creams among the most effective treatments for the condition ^[3]. The mometasone-based version delivers the same three-pronged action and is used for the same melasma and hyperpigmentation indications; it is applied to the affected facial skin as a short nightly course, with broad-spectrum daily sun protection considered essential to keep the pigment from returning ^[4].

A specific concern with this formulation is the strength of its steroid. Because mometasone is more potent than the fluocinolone in the standard product, prolonged or unsupervised use raises the risk of corticosteroid side effects on delicate facial skin. A retrospective study of melasma patients using a mometasone-based triple combination found that many had continued it well beyond the recommended period and that a substantial share developed steroid-related problems, most commonly telangiectasia (fine dilated blood vessels), along with skin thinning, excess facial hair and acne-like eruptions; a notable fraction even rated their melasma as worse than before treatment ^[1]. The formulation is therefore best used briefly and under medical supervision, and in some countries such fixed steroid combinations sold without prescription have drawn regulatory criticism. Further risks are shared with the other actives; hydroquinone can rarely cause exogenous ochronosis, and tretinoin commonly produces dryness, peeling and heightened sun sensitivity ^[1].

This is a prescription strength cream. The most common effects are redness, burning, stinging, dryness and peeling, especially early on. The steroid component is the reason it must not be used long term or spread widely, because prolonged topical steroids can thin the skin, cause visible small vessels, trigger acne or perioral dermatitis and, on the face, do lasting damage. Hydroquinone used for too long or too strong can paradoxically cause a bluish black discoloration called ochronosis. Tretinoin makes skin sun sensitive and is not used in pregnancy, so daily broad spectrum sunscreen is essential and courses are kept short and supervised.

This triple-combination cream descends directly from the classic formula devised by the American dermatologist Albert Kligman and colleagues in the 1970s, who combined hydroquinone, tretinoin, and a corticosteroid to treat melasma more effectively than any single agent. The original Kligman formula used a mild corticosteroid, and the later commercially standardized triple combination employed fluocinolone acetonide. The present version modifies that template by substituting mometasone furoate, a more potent corticosteroid, in place of the milder steroid.

Preparations of this type, marketed in some regions under names such as Melacare and Skinshine, became widely prescribed and sold for facial hyperpigmentation, particularly where melasma is prevalent. The three-agent design pairs hydroquinone's inhibition of melanin synthesis with tretinoin's acceleration of pigment-cell turnover and enhanced penetration, while the corticosteroid calms the irritation the other two can cause. The choice of a stronger steroid, however, has raised particular safety concerns about skin thinning and steroid-related side effects with extended use.

As an heir to the celebrated Kligman formula, this triple combination is respected for delivering quicker and more thorough lightening than any of its ingredients could achieve alone. Systematic reviews of melasma consistently rank combination therapies, uniting hydroquinone, a retinoid, and a corticosteroid, among the most effective treatments for stubborn facial pigmentation, and this cream follows that well-validated design.

Hydroquinone suppresses melanin production, tretinoin speeds the shedding of pigmented cells and improves absorption, and the corticosteroid soothes irritation to make the regimen more tolerable. Many patients value its convenience and the visible results it can produce. It is important, though, to be candid that this version uses mometasone, a more potent steroid than the original formulation, which raises a real risk of skin thinning, telangiectasia, and other steroid side effects if used for prolonged or unsupervised periods. Under proper guidance and for limited courses, it remains a potent and time-tested option.